07:00 , Apr 4, 2016 |  BC Week In Review  |  Financial News

ADx NeuroSciences completes venture financing

ADx NeuroSciences N.V., Ghent, Belgium   Business: Diagnostic   Date completed: 2016-03-30   Type: Venture financing   Raised: Not disclosed   Investors: Company founders; private investors   Note: The amount raised is not disclosed.   ...
08:00 , Mar 2, 2015 |  BioCentury  |  Emerging Company Profile

Exosomes for AD

NanoSomiX Inc. is developing a blood-based diagnostic that measures well-studied biomarkers of Alzheimer's disease as a cheaper and less invasive method to diagnose AD than spinal taps or brain imaging. The diagnostic also could be...
07:00 , Mar 19, 2012 |  BioCentury  |  Emerging Company Profile

ADx NeuroSciences: A progressive approach

Current Alzheimer's disease diagnostics do not distinguish between different oligomers of tau and beta amyloid, and thus have little prognostic value. ADx NeuroSciences N.V. is developing oligomer-specific biomarkers that it expects not only to diagnose...
08:00 , Nov 14, 2011 |  BC Week In Review  |  Company News

ADx NeuroSciences, Catholic University Leuven deal

ADx NeuroSciences received exclusive, worldwide rights from the university to develop and commercialize undisclosed antibodies that selectively bind phosphorylated Tau aggregates for use in diagnostics. The company has a right to sublicense. The university is...